Mirati is currently sponsoring clinical trials in multiple programs. Click on a clinical trial below to learn more.
Sitravatinib (MGCD516)
Study 516-005 - Phase 3 of sitravatinib in combination for NSCLC
Phase 3 pivotal trial of sitravatinib in combination with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression on or after platinum-based chemotherapy in combination with checkpoint inhibitor therapy (Study 516-005)
Study 516-003 - Phase 2 of sitravatinib in combination for urothelial carcinoma
Phase 2 clinical trial of sitravatinib in combination with nivolumab in patients with advanced or metastatic urothelial carcinoma (Study 516-003)
Study 516-002 - Phase 2 of sitravatinib in combination for clear cell renal cell cancer
Phase 2 neo-Adjuvant clinical trial of sitravatinib in combination with nivolumab in patients with clear cell renal cell cancer (Study 516-002)
Study 516-001 - Phase 1b of sitravatinib single agent for solid tumors with the CBL gene mutation
KRAS G12C Inhibitor (MRTX849)
Study 849-001 - Phase 1b/2 of single agent MRTX849 for solid tumors with KRAS G12C mutation
Phase 1b/2 clinical trial of single agent MRTX849 in patients with advanced solid tumors that have a KRAS G12C mutation.
To identify clinical trials that match your diagnosis, treatment history and location, call 1-844-893-5530 or use our online Study Locator